Ciprofloxacin-resistant Escherichia coli emerging in a rehabilitation medical center

Diagnostic Microbiology and Infectious Disease

Volumn 29, Issue 3, 1997, Pages 133-138

  Canawati, Hanna N ^a,b   El Farra, Rula ^b   Seymour, Judith ^b   Shimashita, John ^b   Dunn, Donald ^b   Montgomerie, John Z ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b RANCHO LOS AMIGOS NATIONAL REHABILITATION CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPICILLIN; ANTIINFECTIVE AGENT; BERLOCOMBIN; CARBENICILLIN; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DNA TOPOISOMERASE; IMIPENEM; LEVOFLOXACIN; NITROFURANTOIN; NORFLOXACIN; OFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFICACY; ESCHERICHIA COLI; GENE MUTATION; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

EID: 0030681051     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)81802-0     Document Type: Article

References (32)

1. Acar JF, Goldstein FW (1997) Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 24(suppl 1):67S-73S.
2. Blazquez R, Sanchez-Carillo C, Diaz MD, Padilla B (1995) Current situation of ciprofloxacin resistance (cip-R) among Gram-negative bacilli. In: Program and Abstracts of 35th Interscience Conference on Antimicrobial Agents Chemother. San Francisco: Abstract No. E135.
3. Buckner DA, Colonna P, Hindler J, Wagner E (1996) Antimicrobial Susceptibility Summary. Booklet of Clinical Microbiology. Los Angeles, CA: UCLA Medical Center.
4. Canawati H, El-Farra R, Montgomerie JZ (1995) Ciprofloxacin-resistant Eschericia coli: An emerging Resistance in a Rehabilitation Med Ctr. 95th Annual Meetings of the American Society for Microbiology. Washington DC: American Society for Microbiology, Abstract No. C112.
5. Casellas JM, Blanco MG, Pinto ME (1994) The sleeping giant: Antimicrobial resistance. Infect Dis Clin North Am 8:29-45.
6. Chen M, Zhang S, Zhang X, Zhou G, Wang Q (1995) Characteristic in susceptibility of 6,000 isolates to 17 antibiotics in Beijing in 1994. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents Chemother. San Francisco: September 17-20, Abstract No. E134.
7. Dholakia N, Rolston KV, Ho DH, LeBlanc B, Bodey GP (1994) Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother 38:848-852.
8. Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G (1994) Rapid emergence of quinolones resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 38:340-344.
9. Farmer III JJ, Kelly MT (1991) Enterobacteriaceae. In: Manual of Clinical Microbiology. Eds, Balows A, Hausler Jr WJ, Hermann KL, Isenburg HD, Shadomy HJ. Washington, DC: American Society for Microbiology, pp. 360-383.
10. Gimber EA, Shields MD, Canawati HN, Sapico FL, Krishnaswamy A, El-Farra R, Maeder KN, Montgomerie JZ (1997) Bacteriuria with Escherichia coli resistant to ciprofloxacin in patients with spinal cord injury. Infect Control Hosp Epidemiol. In press.
11. Goldstein FW, Acar JF (1995) Epidemiology of quinolone resistance: Europe and North and South America. Drugs 49(suppl 2):36S-42S.
12. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, The Fluoroquinolone Resistance Surveillance Group (1994a) Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. Diagn Microbiol Infect Dis 19: 203-215.
13. Jones RN, Hoban DJ, The North American Ofloxacin Study Group (1994b) North American (United States and Canada) comparative susceptibility of two fluoroquinolones: Ofloxacin and ciprofloxacin. Diagn Microbiol Infect Dis 18:49-56.
14. Jonsson M, Walder M, Forsgren A (1990) First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandinavia. Eur J Clin Microbiol Infect Dis 9:851-853.
15. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R (1994) Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 38:681-687.
16. Kern WV, Markus A, Andriof E (1994) Bacterimia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis 13:161-165.
17. Kresken M, Hafner D, Mittermayer H, Verbist L, Bergogne-Berezin E, Giamarellou H, Esposito S, von Klingeren B, Kayser FH, Reeves DS, Iedemann B, and study group "bacterial resistance" of the PEG for chemotherapy (1994) Prevalence of fluoroquinolone resistance in Europe. Infection 22:(suppl 2):S90-S98.
18. Lehn N, Huffman JS, Kott T, Strassner C, Wagner H, Kronke M, Brachert WS (1996) Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance. J Clin Microbiol 34:597-602
19. Llordes M, Xercavins M, Qunitana S, Carau J (1993) Emergence of ciprofloxacin in Escherichia coli. In: Program and Abstracts of the 6th European Congress of Clin Microbiol Inf Dis. Seville, Spain, March 28-31, Abstract No. 104.
20. Murray PR, Cantrell HF, Lankford RB and the in vitro susceptibility surveillance group (1994) Multicenter evaluation of the in vitro activity of piperacillin/tazobactam compared with eleven selected β-lactam antibiotics and ciprofloxacin against more than 42,000 Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis 19:111-120.
21. Navarro F, Miro E, Izquierdo C, Merlis B, Prats G (1993) Increased resistance of enteropathogens to fluoroquinolones in Barcelona, Spain. Eur J Clin Microbiol Infect Dis 12:645-646.
22. National Committee for Clinical Laboratory Standards (NCCLS) (1993a) Performance Standards for Antimicrobic Disks Susceptibility Tests: Approved Standards M2-A5, 5th ed. Villanova, PA: NCCLS.
23. National Committee for Clinical Laboratory Standards (NCCLS) (1993b) Standard Methods for Dilution Antimicrobial Susceptibility Test for Bacteria Which Grow Aerobically: Approved Standard M2-A3, 3rd ed. Villanova, PA: NCCLS.
24. Othinger M, Conrad S, Haussler K (1995) Fluoroquinolone-resistant Escherichia coli isolates from European cancer centers: genotypes and phenotypes (abstract No. C55). In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC.
25. Posser BLT, Beskid G (1995) Multicenter in vitro comparative study of fluoroquinolones against 25,129 Gram-positive and Gram-negative clinical isolates. Diag Microbiol Infect Dis 21:33-45.
26. Ruiz-Serrano MJ, Gonzales A, Delgado JR, Molina J, Munoz JR, Dominguez J, Ferez Porata MT, Bisquert J (1993) Increase of Escherichia coli resistance to fluoroquinolones. In: Program and Abstracts of the 6th European Congress of Clin Microbiol Inf Dis. Seville, Spain: abstract No. 1042.
27. Shields MD, Canawati H, Sapico FL, Krishnaswamy A, El Farra R, Maeder K, Montgomerie JZ. Bacteriuria with ciprofloxacin-resistant Escherichia coli in patients with spinal cord injury. In: Abstracts of the 95th Annual Meeting of the American Society for Microbiology. Washington DC: Abstract No. L3.
28. Smith BR (1990) National cooperative study of ciprofloxacin susceptibility in the United States. Curr Ther Res 47:962-970.
29. Thornsberry C, Brown SD, Bouchillon SK, Marler J, Rich T, Cheung Yee Y (1991/92). United States Surveillance of Clinical Bacterial Isolates to Ciprofloxacin. Franklin, TN: Institute for Microbiology Research.
30. Thornsberry C (1994) Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States. Infect 22(suppl 2):S80-S89.
31. Turnidge J (1995) Epidemiology of quinolone resistance: Eastern Hemisphere. Drugs 49(suppl 2):S43-S47.
32. Welch WD, Bouchillon SK, Rich T (1995) National antimicrobial resistance of 763,383 bacterial isolates obtained from 150 institutions representing all 50 States. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents Chemother. San Francisco, September 17-20, Abstract No. E132.